Execs expect study to expand market for implantable heart devices

06/15/2009 | Reuters

Medical-device executives are optimistic that the market for cardiac resynchronization therapy devices and other expensive implants could double if the MADIT-CRT study yields positive results. The Boston Scientific-sponsored study aims to show that combining defibrillators with CRT devices could delay the progression of early-stage heart failure. An analyst with FAF Advisors, however, said reimbursement will play a key role in boosting the sales of the combination products.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health